超越常规CT:双能CT在腹部恶性肿瘤治疗反应监测中的作用
本文综述双能CT(DECT)在腹部恶性肿瘤治疗反应评估中的作用。常规形态学评估长期作为标准,而DECT基于碘定量的方法正被研究作为评估肿瘤血管性和生理学的替代指标,在靶向治疗患者中尤为重要。本文讨论DECT在评估腹部恶性肿瘤治疗反应中的当前和新兴作用。
要点
- DECT基于碘定量的方法正被研究作为评估肿瘤血管性和生理学的替代指标。
- DECT在靶向治疗患者的治疗反应评估中可能尤为重要。
- 常规形态学评估仍是长期以来的标准,DECT拓展了从反应评估到患者选择和结局预测的范围。
核心结论
- DECT基于碘定量的方法正被研究作为评估肿瘤血管性和生理学的替代指标,在靶向治疗患者中尤为重要,本文讨论其在腹部恶性肿瘤治疗反应评估中的当前和新兴作用。
研究设计与样本
- 综述文章,讨论DECT在评估腹部恶性肿瘤患者治疗反应中的当前和新兴作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
In the era of precision medicine, imaging plays a critical role in evaluating treatment response to various oncologic therapies. For decades, conventional morphologic assessments using cross-sectional imaging have been the standard for monitoring the effectiveness of systemic and locoregional therapies in patients with cancer. However, the development of new functional imaging tools has widened the scope of imaging from mere response assessment to patient selection and outcome prediction. Dual-energy CT (DECT), known for its superior material differentiation capabilities, shows promise in enhancing treatment response evaluation. DECT-based iodine quantification methods are increasingly being investigated as surrogates for assessing tumor vascularity and physiology, which is particularly important in patients undergoing emerging targeted therapies. The purpose of this review article is to discuss the current and emerging role of DECT in assessing treatment response in patients with malignant abdominal tumors. Keywords: CT-Dual Energy, Transcatheter Tumor Therapy, Tumor Response, Iodine Uptake, Therapeutic Response © RSNA, 2025.
引用
- Pourvaziri A, Mroueh N, Cochran RL, et al. Beyond Conventional CT: Role of Dual-Energy CT in Monitoring Response to Therapy in Abdominal Malignancies. Radiol Imaging Cancer. 2025. PMID: 40249270. doi:10.1148/rycan.240142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。